Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.2018 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.2018 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2018 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.2018 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2018 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2018 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.2018 | 0.5 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.2018 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2018 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.2018 | 0.5 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.2018 | 0.5 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.2018 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.2018 | 0.5 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.2018 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.2018 | 0.5 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.2018 | 0.5 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.2018 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.2018 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.2018 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.2018 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | > 100 uM | Antibacterial activity against Escherichia coli DH5[alpha] assessed as complete inhibition of bacterial growth measured upto 24 hrs by broth dilution assay | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.